Clinical Trial Update: Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating vorinostat after stem cell transplant in patients with high-risk lymphoma; the study is completed and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Small Intestine Cancer

Drugs mentioned

• Vorinostat (vorinostat)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Lymphoma, Small Intestine Cancer | Phase 1 | Status: COMPLETED | Results posted: 2015-07-16